FRA:IX1 • US45168D1046
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IDEXX LABORATORIES INC (IX1.DE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-08-13 | Credit Suisse | Maintains | Outperform |
| 2021-08-03 | Goldman Sachs | Maintains | Neutral |
| 2021-08-02 | Barclays | Maintains | Overweight |
| 2021-07-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2021-02-17 | Barclays | Initiate | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.661B 8.72% | 3.898B 6.46% | 4.304B 10.42% | 4.772B 10.88% | 5.182B 8.59% | 5.661B 9.24% | 6.158B 8.78% | 6.707B 8.92% | 7.77B 15.85% | 8.424B 8.42% | 9.096B 7.98% | |
| EBITDA YoY % growth | 1.213B 19.63% | 1.263B 4.09% | 1.509B 19.53% | 1.692B 12.10% | 1.873B 10.70% | 2.09B 11.59% | 2.335B 11.72% | 2.584B 10.66% | 3.102B 20.05% | 3.426B 10.44% | 3.761B 9.78% | |
| EBIT YoY % growth | 1.098B 21.73% | 1.133B 3.15% | 1.364B 20.43% | 1.535B 12.52% | 1.707B 11.21% | 1.909B 11.83% | 2.148B 12.52% | 2.386B 11.08% | 2.917B 22.25% | 3.23B 10.73% | 3.552B 9.97% | |
| Operating Margin | 30.00% | 29.07% | 31.70% | 32.17% | 32.94% | 33.72% | 34.88% | 35.57% | 37.54% | 38.34% | 39.05% | |
| EPS YoY % growth | 10.07 25.40% | 11.25 11.72% | 13.07 16.18% | 14.81 13.30% | 16.72 12.92% | 18.98 13.52% | 21.08 11.06% | 23.75 12.66% | 30.15 26.96% | 33.78 12.04% | 37.57 11.20% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 3.47 17.25% | 4.01 10.39% | 3.84 13.01% | 3.48 13.11% | 3.93 13.38% | 4.50 12.42% | 4.33 12.61% | 4.01 15.05% | 4.41 11.99% | 5.17 14.80% | 4.88 12.68% | 4.46 11.21% |
| Revenue Q2Q % growth | 1.142B 14.38% | 1.222B 10.14% | 1.213B 9.75% | 1.196B 9.67% | 1.224B 7.18% | 1.324B 8.35% | 1.317B 8.57% | 1.301B 8.78% | 1.34B 9.48% | 1.447B 9.29% | 1.448B 9.95% | 1.427B 9.68% |
| EBITDA Q2Q % growth | 404.6M 15.40% | 456.94M 3.17% | 440.78M -4.45% | 401.69M -12.83% | 443.99M 9.74% | 489.71M 7.17% | 478.56M 8.57% | 449.09M 11.80% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 364.36M 15.11% | 415.14M 11.28% | 398.49M 12.30% | 359.31M 13.85% | 399.61M 9.67% | 458.86M 10.53% | 440.27M 10.48% | 398.02M 10.77% | 454.92M 13.84% | 515.1M 12.26% | 493.68M 12.13% | 442.68M 11.22% |
All data in USD
22 analysts have analysed IX1.DE and the average price target is 633.2 EUR. This implies a price increase of 29.33% is expected in the next year compared to the current price of 489.6.
IDEXX LABORATORIES INC (IX1.DE) will report earnings on 2026-05-05, before the market open.
The consensus EPS estimate for the next earnings of IDEXX LABORATORIES INC (IX1.DE) is 3.47 EUR and the consensus revenue estimate is 1.14B EUR.
The number of analysts covering IDEXX LABORATORIES INC (IX1.DE) is 22.